EVOK - Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI | Benzinga
Expanded State Medicaid Access for GIMOTI
Achieved highest ever monthly GIMOTI prescription fills in May 2024
Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer
SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation.
ASPN Pharmacy Platform
In November 2023, Evoke transitioned its pharmacy distribution partnership from vitaCare to ASPN Pharmacies. This strategic move has streamlined the prescription process for healthcare providers, ensuring that patients receive GIMOTI promptly. Over two quarters of collaboration with ASPN, Evoke has improved percentages of GIMOTI prescriptions converted to fills, and initial data show record-high prescription fills in April and May. ASPN's comprehensive servicing platform provides holistic advantages for our business, healthcare providers, and patients, reinforcing Evoke's mission to reach as many patients as possible.
"We continue to make inroads into the diabetic gastroparesis market and believe we are well positioned to improve the health and daily life of patients suffering with symptoms of this debilitating disease. We have invested significantly in generating evidence to demonstrate the value of GIMOTI to patients, providers and payers. Partnering with ASPN affords Evoke access to state of the art tools and capabilities and allows us to ensure we can deliver GIMOTI quickly, improve patient and provider experience and ramp up for future demand," said Chris Quesenberry, Chief Commercial Officer for GIMOTI.
Medicaid access through Pharmacy Partnerships
In May 2024, Evoke, through Eversana, began expanding our filling pharmacy network from a single central organization to an additional four regional pharmacies. This is intended to allow for improved coverage, reimbursement and speed to deliver GIMOTI to patients in need. Some of the states where access to GIMOTI will improve based on expanded distribution include: Arkansas, Connecticut, Georgia, Illinois, and Michigan, Mississippi, Rhode Island and Tennessee. In our first full month with these additional pharmacies, Evoke is already realizing additional GIMOTI covered prescriptions through insurers, especially Medicaid patients. Evoke anticipates further expansion of our pharmacy distribution in the coming months.
"Halfway into 2024, as prescriptions continue to grow, we are executing on our distribution expansion strategy and are seeing improved growth trajectory of access and sales for GIMOTI. The combination of the shift to ASPN and the expansion of additional regional pharmacies is yielding results to help unlock GIMOTI's true market potential," stated Matt D'Onofrio, Chief Executive Officer of Evoke Pharma.
Leadership Changes and Operational Enhancements
In alignment with Evoke's growth objectives, we are pleased to announce the promotion of Mark Kowieski, formerly our VP of Finance, to the role of Chief Financial Officer in May 2024. ...